Variables | Observations (N= 25) |
---|---|
Females, n (%) | 19 (76%) |
Mean age ± SD, yr (IQR) | 56.2 ± 14.9 (26 to 77) |
Disease duration, yr | 12.3 [4.0 to 14.1] (0.9; 42.7) |
RF-positive, n (%) | 21 (84%) |
Anti-CCP-positive, n (%) | 22 (88%) |
Mean DAS-28-CRP score (0 to 10) | 4.8 ± 1.3 [2.2 to 6.8] |
CRP, mg/L | 20.9 [4 to 30] (1; 117) |
VAS global (scale 0 to 100) | 62.5 [41 to 83] |
Tender joint count, 28 joints | 7.1 [4 to 9] (0; 25) |
Swollen joint count, 28 joints | 7.8 [4 to 9] (1; 21) |
DMARD monotherapy | |
MTX, n (%) | 2 (8%) |
SZS, n (%) | 3 (12%) |
LFU, n (%) | 2 (8%) |
DMARD combination treatment | |
MTX + SZS, n (%) | 4 (16%) |
MTX + SZS + HCQ, n (%) | 3 (12%) |
Biologic DMARDs (%) | 8 (32%) |
Prednisolone monotherapy, 5 mg/day | 2 (8%) |
No DMARDs (%) | 1 (4%) |